Cure8 research brief
An extra mRNA COVID-19 vaccine dose produced only modest increases in antibody and T‑cell responses in immunosuppressed children (including those with IBD), so vaccine protection may still be lower than in healthy children.
Pediatric patients with IBD on immunosuppression; parents/caregivers; pediatric gastroenterologists and clinicians advising on vaccination for immunocompromised children.
Researchers enrolled immunosuppressed children (including those with IBD, nephrotic syndrome, or hematological cancers) who had completed two mRNA vaccine doses at least 150 days earlier and measured anti‑spike IgG, neutralizing titers, and cellular responses before and after a third dose.
The additional dose produced modest increases in antibody and cellular responses in the combined immunosuppressed group; children with hematological cancers showed larger relative increases but still had much lower absolute responses than healthy controls.
The study concludes that while a third mRNA dose can raise immune markers in some immunosuppressed children, overall responses remained lower than in healthy peers and the clinical benefit (protection against infection or severe disease) is uncertain.
Findings are from the article abstract and report immunologic markers rather than clinical outcomes; subgroup sample sizes were small, so results should be interpreted cautiously.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Faster remission can reduce symptoms, school disruption, and steroid exposure for children with IBD. If earlier infliximab level checks reliably speed remission, clinicians could adjust dosing sooner to improve outcomes.
UGI involvement in children with IBD was common and linked to a more severe disease course — lower remission rates and more frequent need for biologic therapy — which could affect monitoring and treatment planning.
If reliable, an earlier day‑3 PUCAI cutoff could help identify children with flare‑related ASUC who are unlikely to respond to IV steroids and who may benefit from earlier planning for second‑line therapy rather than...
